Today, NAMD urged Congressional committees of jurisdiction to take immediate action to avert the 52% increase in Medicare Part B premiums slated to take effect on January 1, 2016. The letter notes that the financial burden of this increase falls primarily on Medicaid programs, as the premium increase applies to only 30% of Part B […]
NAMD provided written comments to the Health Resources and Services Administration on its proposed rule addressing ceiling prices and manufacturer civil monetary penalties in the 340B drug discount program. Read the full letter here.
Today, the National Association of Medicaid Directors submitted comments to Vicki Wachino, Director, Center for Medicaid & CHIP Services, Centers for Medicare & Medicaid Services at the U.S. Department of Health and Human Services on the proposed rule, Medicaid and Children’s Health Insurance Programs; Medicaid Managed Care, CHIP Delivered in Managed Care, Medicaid and CHIP Comprehensive Quality Strategies and Revisions […]
Today, Matt Salo, executive director of the National Association of Medicaid Directors, gave testimony before the Energy and Commerce Committee, Subcommittee on Health on “Examining the Administration’s Approval of Medicaid Demonstration Projects.” Read the full testimony here.
NAMD submitted comments to the Centers for Medicare and Medicaid Services on the proposed rule on the Application of Mental Health Parity Requirements to Coverage Offered by Medicaid Managed Care Organizations, the Children’s Health Insurance Program (CHIP), and Alternative Benefit Plans. Read the full letter here.
NAMD sent a letter to the Health Resources and Services Administration (HRSA) and the Centers for Medicare and Medicaid Services (CMS) to share our recent white paper discussing operational challenges in Medicaid’s interaction with the 340B drug discount program. The white paper is available here. Read the full letter here.
The National Association of Medicaid Directors sent a letter to the leaders of the House Energy and Commerce Committee regarding the impact to the Medicaid program from federal legislative efforts to incentivize and expedite high-cost cure-like pharmaceutical treatments and devices. Read the full letter here.
The National Association of Medicaid Directors submitted a letter to the Centers for Medicare and Medicaid Services Acting Administrator Slavitt. The letter acknowledges progress made to improve Medicaid and Exchange interactions and calls for additional steps to improve the beneficiary experience and efficiency of operations. Read the full letter here.